NeuroBo Pharmaceuticals to Participate in H.C. Wainwright Global Life Sciences Conference

Rhea-AI Summary

NeuroBo Pharmaceuticals (Nasdaq: NRBO) announced its participation in the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. Senior Vice President Akash Bakshi and Commercial Advisor Seth Reno will present a corporate overview, including updates on the ongoing phase 2/3 clinical trial of ANA001, a treatment for moderate to severe COVID-19. The presentation will be available from 7:00 am ET on March 9, with a 90-day archived replay. NeuroBo is focused on developing therapies for various diseases, including its lead program, ANA001, and others addressing neuropathic and neurodegenerative conditions.

BOSTON, March 5, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced that Company management will participate in the upcoming H.C. Wainwright Global Life Sciences Conference taking place virtually from March 9-10, 2021. 

Akash Bakshi, Senior Vice President and Chief Operating Officer of NeuroBo and Seth Reno, Commercial Advisor of NeuroBo, will present a corporate overview at the conference, including an update on the status of the ongoing phase 2/3 study of lead program, ANA001, in moderate and severe COVID-19 patients.

The presentation will be available beginning March 9, at 7:00 am ET. A webcast of the presentation will be available on the "Events and Presentations" section of NeuroBo's website at: neurobopharma.com/events-presentations. An archived replay will be available for a period of 90 days after the conference.

About NeuroBo Pharmaceuticals

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on developing and commercializing multi-modal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases, has a current portfolio of four drug candidates. The company's recently acquired ANA001 candidate is a proprietary oral niclosamide formulation in development as a treatment for patients with moderate to severe COVID-19 (patients not requiring ventilators). Niclosamide is a potential oral antiviral and anti-inflammatory agent with a long history of use and a well-understood safety profile in humans. ANA001 is currently being studied in a 60-subject Phase 2/3 clinical trial conducted at up to 20 clinical sites in the U.S. Niclosamide has demonstrated both antiviral and immunomodulatory activity with possible downstream effects on coagulation abnormalities observed in COVID-19. The company's NB-01 candidate has been shown in a Phase 2 study to significantly reduce pain symptoms associated with painful diabetic neuropathy (PDN), with a superior safety profile when compared to currently available treatments. Due to global COVID-19 crisis, a planned Phase 3 study was postponed. In the interim, NeuroBo is exploring a potential orphan drug indication targeting chronic pain for NB-01. NeuroBo's NB-02 drug candidate is focused on the treatment of Alzheimer's disease and neurodegenerative diseases associated with the pathological dysfunction of tau proteins in the brain. The company's fourth program, Gemcabene, was developed for the treatment of dyslipidemia, a serious medical condition that increases the risk of life-threatening cardiovascular disease.

For more information visit: https://www.neurobopharma.com.

Forward Looking Statements

Any statements in this press release that are not statements of historical fact constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, statements regarding the development timeline for niclosamide for the treatment of COVID-19, the market size for COVID-19-related therapeutics and the competitive advantages of ANA001, the potential benefits of ANA001 as a treatment for patients with moderate to severe COVID-19 (patients not requiring ventilators), and potential milestone payments and royalties that may become due to the former equity holders of ANA under the acquisition agreement. Forward-looking statements are usually identified by the use of words, such as "believes," "anticipates," "expects," "intends," "plans," "may," "potential," "will," "could" and similar expressions. Actual results may differ materially from those indicated by forward-looking statements as a result of various important factors and risks. These factors, risks and uncertainties include, but are not limited to: the failure to obtain all of the benefits or recognize all of the synergies anticipated from the ANA acquisition; the integration of ANA potentially diverting management resources from operational matters and other strategic opportunities; the effect of future milestone payments and royalties specified in the acquisition agreement on the results of operations and financial position of NeuroBo; the occurrence of health epidemics or contagious diseases, such as COVID-19, and potential effects on NeuroBo's business, clinical trial sites, supply chain and manufacturing facilities; NeuroBo's ability to continue as a going concern; the timing of completion of NeuroBo's planned clinical trials, including with respect to ANA001; the timing of the availability of data from NeuroBo's clinical trials, including with respect to ANA001;  the clinical utility, potential benefits and market acceptance of NeuroBo's product candidates, including ANA001; ; and NeuroBo's need for additional financing to fulfill its stated goals; and other factors discussed in the "Risk Factors" section of NeuroBo's Annual Report on Form 10-K and in our other filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent NeuroBo's views as of the date hereof. NeuroBo anticipates that subsequent events and developments will cause its views to change. However, while NeuroBo may elect to update these forward-looking statements at some point in the future, NeuroBo specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing NeuroBo's views as of any date subsequent to the date hereof.

Contacts:

Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com

View original content:http://www.prnewswire.com/news-releases/neurobo-pharmaceuticals-to-participate-in-hc-wainwright-global-life-sciences-conference-301241340.html

SOURCE NeuroBo Pharmaceuticals, Inc.

FAQ

When will NeuroBo Pharmaceuticals present at the H.C. Wainwright Global Life Sciences Conference?

NeuroBo Pharmaceuticals will present at the conference on March 9, 2021, starting at 7:00 am ET.

What is the focus of the presentation by NeuroBo Pharmaceuticals at the conference?

The presentation will cover a corporate overview and updates on the phase 2/3 study of ANA001 for moderate to severe COVID-19 patients.

How can I access the presentation by NeuroBo Pharmaceuticals?

The presentation will be available on NeuroBo's website under the 'Events and Presentations' section starting March 9, 2021.

What are the key trials NeuroBo is conducting related to COVID-19?

NeuroBo is conducting a phase 2/3 clinical trial for its lead program, ANA001, focused on treating moderate to severe COVID-19.

What types of diseases does NeuroBo Pharmaceuticals target?

NeuroBo Pharmaceuticals develops therapies for viral, neuropathic, and neurodegenerative diseases, including its COVID-19 treatment, ANA001.

What is ANA001 and what is its significance?

ANA001 is a proprietary oral formulation of niclosamide in development as a treatment for patients with moderate to severe COVID-19.